Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Skin Cancer
Interventions: OIR Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stroke, Acute, Ischemic Stroke, Acute
Interventions: EndovascularThrombectomy, Endovascular thrombectomy with any FDA-approved device; Procedure · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Premalignant Lesion
Interventions: Nivolumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
Interventions: Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab; Radiation · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 10
States / cities: Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more

Conditions: Gastric Cancer, Intestinal Metaplasia of Gastric Mucosa, Helicobacter Pylori Infection, Atrophic Gastritis
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 35 Years to 84 Years
Enrollment: 600 participants
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Low Back Pain
Interventions: Bupivacaine TTS (Bupivacaine Patch), Placebo patch; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Tempe, Arizona • La Mesa, California • Torrance, California + 18 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more

Conditions: Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
Interventions: polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy; Genetic · Other · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Oxnard, California • Ormond Beach, Florida + 21 more

Conditions: Tobacco Use
Interventions: EX program; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 120 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Laboratory Biomarker Analysis, Radiation Therapy; Other · Radiation
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: Buffalo, New York • Cheektowaga, New York

Conditions: Photoallergy
Interventions: SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Pinellas Park, Florida

Conditions: Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory, Approved Alternative Therapy
Interventions: PV-10 (10% rose bengal disodium); Drug
Lead sponsor: Provectus Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 3
States / cities: Louisville, Kentucky • Bethlehem, Pennsylvania • Houston, Texas

Conditions: Osteoarthritis, Knee
Interventions: AXS-02, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 54
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 49 more

Conditions: Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
Interventions: TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, TTI-621 + T-Vec, TTI-621 + radiation; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Duarte, California • New York, New York • Portland, Oregon + 3 more

Conditions: Breast Cancer
Interventions: OneMark device; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Comedogenicity
Interventions: Lotion, Negative Control; Device · Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Subchondral Cysts, Subchondral Bone Edema, Bone Marrow Edema, Insufficiency Fractures, Avascular Necrosis of Hip, Femoroacetabular Impingement, Dysplasia; Hip
Interventions: Subchondroplasty Procedure with AccuFill; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 6
States / cities: Rancho Mirage, California • Gulf Breeze, Florida • Rockford, Illinois + 3 more

Conditions: Oral Cancer
Interventions: Fluorescence Spectroscopy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Molluscum Contagiosum
Interventions: Cantharidin; Drug
Lead sponsor: Steven R Cohen; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Vital Signs
Interventions: VSP System - NEHB Configuration, VSP System - PAL Configuration; Device
Lead sponsor: LifeWatch Services, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Nevus, Racial Melanosis, Primary Acquired Melanosis, Conjunctival Malignant Melanoma
Interventions: HRT III with Non-Contact Cornea Rostock Module; Procedure
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Breast Cancer
Interventions: cytology specimen collection procedure; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cervical Intraepithelial Neoplasia, Cervical Dysplasia
Interventions: 9-valent HPV vaccine, Imiquimod; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Melanoma Detection by Oblique-Incidence Optical Spectroscopy

Endovascular Therapy for Large Core Patients With Uncertain Response to Thrombectomy

Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

The GAstric Precancerous Conditions Study

Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Be A Quitter: Illinois Small Business EX Program Dissemination

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

To Test for Photo Allergy Reaction of Sunscreens

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance

Human Comedogenicity Test

SCP Hip Outcomes Study

Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

Vital Signs Patch Early Feasibility and Usability Study v1.0

In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions

Core Biopsies for Establishing a Breast Tumor Tissue Repository

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)